SLS stock forecast
Our latest prediction for SELLAS Life Sciences Group, Inc.'s stock price was made on the Feb. 8, 2017 when the stock price was at 24.90$.
In the short term (2weeks), SLS's stock price should underperform the market by -1.68%. During that period the price should oscillate between -14.33% and +26.61%.
In the medium term (3months), SLS's stock price should underperform the market by -3.96%. During that period the price should oscillate between -29.10% and +53.24%.Get email alerts
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the development and commercialization of novel cancer immunotherapeutics for cancer indications. Its product galinpepimut-S, or GPS, is an immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, which targets the Wilms tumor 1, or WT1, protein. Its products include galinpepimut-S and nelipepimut-S. The company was founded on April 3, 2006 and is headquartered in New York, NY.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -8.63$ per share.
The book value per share is -0.13$
Three months stock forecastFeb. 8, 2017
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|